Why Thrombolysis is Not Indicated in This Case
In a patient with transient left-sided weakness that has already improved, a currently normal neurological examination, and imaging at 3.5 hours showing no infarction or vessel occlusion, thrombolysis should be withheld because there is no identifiable target for reperfusion therapy and the risk of hemorrhagic complications outweighs any potential benefit.
Core Reasoning: No Target for Thrombolysis
The fundamental principle of thrombolytic therapy is to restore blood flow to ischemic but salvageable brain tissue. In this scenario, three critical elements are absent:
1. No Vessel Occlusion on MRA
- Thrombolysis works by dissolving clots in occluded vessels 1
- Without a demonstrable large vessel occlusion (LVO), there is no mechanical obstruction to dissolve
- The MRA showing patent vessels indicates blood flow is already restored or was never significantly compromised
2. No Infarction on MRI/DWI
- MRI with diffusion-weighted imaging (DWI) is highly sensitive and specific for detecting acute ischemia 2
- The absence of DWI changes at 3.5 hours strongly suggests no significant ischemic injury occurred
- This indicates either a transient ischemic attack (TIA) or a stroke mimic rather than an evolving infarction requiring intervention
3. Complete Clinical Resolution
- The currently normal neurological examination indicates spontaneous reperfusion has already occurred
- There is no ongoing neurological deficit to improve
The Mild/Improving Symptoms Controversy
While guidelines acknowledge that mild or rapidly improving symptoms have been a common reason for exclusion from thrombolysis 3, the evidence supporting treatment in such cases applies to a fundamentally different clinical scenario:
- The 2007 guideline data showing benefit in mild/improving strokes 3 involved patients who still had demonstrable vessel occlusions or visible infarctions on imaging
- Approximately one-third of patients with rapidly improving symptoms can deteriorate 3, but this risk applies when there is an underlying vascular lesion (occlusion or stenosis) that could re-occlude
- The Japan Stroke Society (2022) states thrombolysis "may be reasonable after careful consideration" in mild stroke 1, but this is Grade C evidence and assumes the presence of confirmed ischemia
Critical distinction: Your patient has both clinical improvement and negative imaging for both infarction and vessel occlusion. This combination indicates the pathological process has resolved.
Risk-Benefit Analysis
Risks of Thrombolysis in This Patient:
- Symptomatic intracranial hemorrhage (approximately 6% risk in treated patients)
- Systemic bleeding complications
- Angioedema (rare but serious)
Potential Benefits:
- None - there is no occluded vessel to recanalize and no ischemic tissue to salvage
Common Clinical Pitfalls to Avoid
Don't treat based on history alone: The initial presentation of left-sided weakness is concerning, but the current clinical and imaging picture supersedes the historical symptoms
Don't assume imaging is falsely negative: At 3.5 hours, MRI/DWI has excellent sensitivity for acute ischemia 2. A truly negative study is reliable
Don't confuse TIA with stroke requiring thrombolysis: This presentation is most consistent with a TIA (transient symptoms, normal exam, negative imaging). TIAs require urgent secondary prevention (antiplatelet therapy, risk factor modification, vascular imaging for stenosis) but not thrombolysis
Recognize stroke mimics: With complete resolution and negative imaging, consider alternative diagnoses (seizure with Todd's paralysis, migraine with aura, functional neurological disorder)
Appropriate Management Instead
Focus on secondary stroke prevention:
- Initiate antiplatelet therapy (aspirin 160-300 mg within 48 hours) 1
- Complete vascular workup (carotid ultrasound, cardiac monitoring for atrial fibrillation)
- Aggressive risk factor modification (blood pressure control, lipid management, diabetes control)
- Consider dual antiplatelet therapy (aspirin + clopidogrel) for high-risk TIA 1
The absence of both a vascular target and tissue at risk makes thrombolysis not just unnecessary, but potentially harmful in this specific clinical context.